search
Back to results

Bioequivalency Study of Terbinafine Tablets Under Fed Conditions

Primary Purpose

Onychomycosis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Terbinafine
Sponsored by
Roxane Laboratories
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Onychomycosis

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

Exclusion Criteria:

  • Positive test for HIV, Hepatitis B, or Hepatitis C.
  • Treatment with known enzyme altering drugs.
  • History of allergic or adverse response to terbinafine or any comparable or similar product.

Sites / Locations

  • Gateway Medical Research, Inc.

Outcomes

Primary Outcome Measures

Bioequivalence

Secondary Outcome Measures

Full Information

First Posted
January 15, 2008
Last Updated
January 19, 2018
Sponsor
Roxane Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT00602251
Brief Title
Bioequivalency Study of Terbinafine Tablets Under Fed Conditions
Official Title
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fed Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
March 2004 (undefined)
Primary Completion Date
April 2004 (Actual)
Study Completion Date
April 2004 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Roxane Laboratories

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Onychomycosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Terbinafine
Primary Outcome Measure Information:
Title
Bioequivalence
Time Frame
Baseline, Two period, Twenty-one day washout

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to terbinafine or any comparable or similar product.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Herrmann, MD
Organizational Affiliation
Cetero Research, San Antonio
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gateway Medical Research, Inc.
City
Saint Charles
State/Province
Missouri
ZIP/Postal Code
63301
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Bioequivalency Study of Terbinafine Tablets Under Fed Conditions

We'll reach out to this number within 24 hrs